Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

4.61 0.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.32

Max

4.63

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
EPS	-0.503
Darbinieki	106
EBITDA	2.2M -35M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+68.36% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	62M 357M
Iepriekšējā atvēršanas cena	4.39
Iepriekšējā slēgšanas cena	4.61

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. jūl. 23:56 UTC

eBay Inc. shares are trading lower in after-market hours, with no specific company news identified. The stock remains near the midpoint of its one-month trading range.

2026. g. 27. jūl. 23:56 UTC

Steel Dynamics Inc shares are trading lower in after-market hours. No specific company news was identified to explain the price movement.

2026. g. 27. jūl. 23:56 UTC

Alibaba Group Holding Ltd shows a slight gain in after-market trading, reflecting positive market sentiment. The stock remains above its 20-day moving average.

2026. g. 27. jūl. 23:56 UTC

PepsiCo Inc. shares remained roughly flat during after-market hours, trading within a narrow range around the middle of their one-month range.

2026. g. 27. jūl. 23:56 UTC

Monday.Com Ltd. shares are lower in after-market trading, fluctuating within a narrow range without specific news driving the decline.

2026. g. 27. jūl. 23:56 UTC

Correlated Moves

Kulicke and Soffa Industries shares declined in after-market trading, reflecting broader weakness in the semiconductor sector and a drop in the Nasdaq 100 Index.

2026. g. 27. jūl. 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

2026. g. 27. jūl. 23:56 UTC

Correlated Moves

News

Diamondback Energy gained during after-market hours, buoyed by strong revenue growth and a favorable market position, with shares peaking above Monday's close.

2026. g. 27. jūl. 23:56 UTC

Under Armour Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

2026. g. 27. jūl. 23:56 UTC

Whirlpool Corp shares are higher in after-market hours, reflecting a modest increase since Monday's close amid positive sentiment in European markets.

2026. g. 27. jūl. 23:56 UTC

Archer-Daniels-Midland Co is rising in after-market trading, reversing three sessions of declines. No specific news was identified to explain this movement.

2026. g. 27. jūl. 23:56 UTC

Matador Resources Co shares are higher in after-market trading following Monday's close, despite remaining below their 20-day moving average.

2026. g. 27. jūl. 23:56 UTC

JD.Com Inc. shares declined in after-market trading, despite a strong one-month gain and trading above its 20-day moving average. No specific news was identified.

2026. g. 27. jūl. 23:56 UTC

Correlated Moves

Costco shares are lower in after-market trading, following a slight decline in the Nasdaq 100 Index. The stock remains above its 20-day moving average.

2026. g. 27. jūl. 23:56 UTC

Social Media

General Motors plans a $6 billion investment in U.S. manufacturing, including an expansion at its Orion Township plant. Shares are roughly flat in after-market trading.

2026. g. 27. jūl. 23:56 UTC

Shell PLC shares showed little change in after-market trading. The stock remains above its 20-day moving average amid positive sentiment in European markets.

2026. g. 27. jūl. 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

2026. g. 27. jūl. 23:56 UTC

Trimble Inc shares are lower in after-market hours following Monday's close. The stock remains above its 20-day moving average despite the decline.

2026. g. 27. jūl. 23:52 UTC

Mexico's Business Confidence Data Release on August 3, 2026, Expected to Reflect Cautious Sentiment Amid Global Market Volatility and Inflationary Pressures.

2026. g. 27. jūl. 23:52 UTC

U.S. Initial Jobless Claims Expected at 204,000 Amid Positive Labor Market Sentiment and Fed Policy Speculation

2026. g. 27. jūl. 23:52 UTC

Australia's Building Permits Expected to Decline by 0.5% in June Amidst Ongoing Weakness in Housing Construction and Elevated Borrowing Costs

2026. g. 27. jūl. 23:52 UTC

Weis Markets shares declined after-market, remaining about 4.47% below their 20-day moving average. No specific news was identified to explain the movement.

2026. g. 27. jūl. 23:52 UTC

Xylem Inc shares are higher in after-market trading, continuing a trend of four consecutive sessions of gains and remaining above the 20-day moving average.

2026. g. 27. jūl. 23:51 UTC

Trustmark Corp shares are higher during after-market hours, moving from a low of -0.04% to a high of 0.95% since Monday's close.

2026. g. 27. jūl. 23:51 UTC

Correlated Moves

Vanguard Total Bond Market ETF trades higher after-market, reflecting broader market trends amid easing geopolitical tensions and a drop in oil prices.

2026. g. 27. jūl. 23:51 UTC

J B Hunt Transport Services Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the movement.

2026. g. 27. jūl. 23:51 UTC

Social Media

Correlated Moves

Shares lower in after-market trading; call writer profits $1.28 million.

2026. g. 27. jūl. 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

2026. g. 27. jūl. 23:51 UTC

News

Event

UDR Inc reported second-quarter net income of $69.035 million. Shares declined in after-market trading amid concerns over flat revenue and rising costs.

2026. g. 27. jūl. 23:51 UTC

News

L3Harris Technologies has secured Pentagon agreements to boost missile defense production, but shares are trading lower in after-market hours.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

68.36% augšup

Prognoze 12 mēnešiem

Vidējais 7.29 USD 68.36%

Augstākais 11 USD

Zemākais 4 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.